Skip to main content

Table 1 Demographic and pathological characteristics according to tumor location: overall cohort and matched cohort

From: Influence of tumor location on short- and long-term outcomes after laparoscopic surgery for rectal cancer: a propensity score matched cohort study

Variables Overall patients Matched patients
LRC (n = 138) M/HRC (n = 235) P value LRC (n = 99) M/HRC (n = 99) P value
Sex, n (%)    0.700    1.000
 Male 78 (56.5) 128 (54.5)   52 (52.5) 52 (52.5)  
 Female 60 (43.5) 107 (45.5)   47 (47.5) 47 (47.5)  
Age (y), n (%)    0.027    0.802
 ≤ 60 81 (58.7) 110 (46.8)   54 (54.5) 58 (58.6)  
 >60 57 (41.3) 125 (53.2)   45 (45.5) 41 (41.4)  
ASA, n (%)    0.873    1.000
 I 68 (49.3) 112 (47.7)   51 (51.5) 51 (51.5)  
 II 57 (41.3) 97 (41.3)   39 (39.4) 39 (39.4)  
 III 13 (9.4) 26 (11.1)   9 (9.1) 9 (9.1)  
BMI (kg/m2), n (%)    0.113    0.669
 <25 73 (52.9) 144 (61.3)   52 (52.5) 55 (55.6)  
 ≥ 25 65 (47.1) 91 (38.7)   47 (47.5) 44 (44.4)  
Preoperative CEA (ng/ml), n (%)    0.374    0.644
 ≤ 5 100 (72.5) 160 (68.1)   67 (67.7) 70 (70.7)  
 >5 38 (27.5) 75 (31.9)   32 (32.3) 29 (29.3)  
Preoperative CA19–9 (U/ml), n (%)    0.665    0.621
 ≤ 37 128 (92.8) 215 (91.5)   91 (91.9) 89 (89.9)  
 >37 10 (7.2) 20 (8.5)   8 (8.1) 10 (10.1)  
Preoperative CA72.4 (U/ml), n (%)    0.311    0.267
 ≤ 6.7 121 (87.7) 197 (83.8)   85 (85.9) 90 (90.9)  
 >6.7 17 (12.3) 38 (16.2)   14 (14.1) 9 (9.1)  
Tumor differentiation, n (%)    0.161    0.592
 Well + moderate 111 (80.4) 202 (86.0)   81 (81.8) 78 (78.8)  
 Poor 27 (19.6) 33 (14.0)   18 (18.2) 21 (21.2)  
Pathological T stage, n (%)    <0.001    0.461
 pT0–2 64 (46.4) 66 (28.1)   39 (39.4) 34 (34.3)  
 pT3–4 74 (53.6) 169 (71.9)   60 (60.6) 65 (65.7)  
Pathological N stage, n (%)    0.352    0.394
 pN0 82 (59.4) 128 (54.5)   52 (52.5) 46 (46.5)  
 pN1–2 56 (40.6) 107 (45.5)   47 (47.5) 53 (53.5)  
TNM stage, n (%)    0.002    0.606
 0-I 52 (37.7) 51 (21.7)   31 (31.3) 25 (25.3)  
 II 30 (21.7) 77 (32.8)   21 (21.2) 21 (21.2)  
 III 56 (40.6) 107 (45.5)   47 (47.5) 53 (53.5)  
Lymphovascular invasion, n (%) 13 (9.4) 37 (15.7) 0.083 11 (11.1) 13 (13.1) 0.663
Perineural invasion, n (%) 2 (1.4) 18 (7.7) 0.009 2 (2.0) 1 (1.0) 1.000
Neoadjuvant therapy, n (%) 66 (47.8) 27 (11.5) <0.001 30 (30.3) 25 (25.3) 0.428
Adjuvant chemotherapy, n (%) 80 (58.0) 117 (49.8) 0.126 59 (59.6) 64 (64.6) 0.464
  1. LRC Low rectal cancer, M/HRC Mid/high rectal cancer, ASA American Society of Anesthesiologists, BMI Body mass index, CEA Carcinoembryonic antigen